Endonovo Therapeutics Inc (ENDV) 0.1701 $ENDV
Biotech's in the News
ACCESSWIRE - Wed Aug 10, 9:19AM CDT
LAS VEGAS, NV / ACCESSWIRE / August 10, 2016 / The name of the game in evaluating development stage biotechnology is patents. How many do they have, how useful are they, and how likely is it they will produce treatments or products for the market? Depending on the combination of answers said company could become an enticing acquisition candidate for some of the bigger fish in the biotech world. Which tends to pay companies and their investors premiums to circumvent their lack of R&D.
BCRX: 4.37 (-0.35), BLCM: 19.72 (+0.54)
Endonovo Therapeutics Files Patent for Treating Chemical and Radiation Injuries Using Next-Generation Biologics
Marketwire Canada - Wed Aug 10, 7:05AM CDT
Next-Generation Biologics Include Cell Therapies and Human Biomolecules Produced by Electromagnetic Stimulation of Adult Stem Cells
Endonovo Therapeutics Announces Issuance of U.S. Patent on Production of Human Biomolecules
Marketwire Canada - Tue Aug 09, 6:00AM CDT
Key Patent Covers Production of Human Proteins Used as Biologics, including EPO, G-CSF, GM-CSF, and IL-2
These Biotech's are Due for a Run
ACCESSWIRE - Thu Aug 04, 12:09PM CDT
It's an Interesting Time in the Biotech Market, and with Labor Day on the Horizon, here's a few Biotechs that could Bring You Closer to Financial Independence
ACRX: 3.57 (-0.10), GSK: 44.32 (-0.08)
OTCQX and OTCQB Companies to Present at 2016 Marcum MicroCap Conference
PR Newswire - Tue May 31, 5:49PM CDT
OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the lineup of OTCQX® Best and OTCQB® Venture Market companies presenting at the Marcum MicroCap Conference, taking place June 1-2nd at the Grand Hyatt New York. The Marcum MicroCap Conference, is dedicated to providing a forum where publicly traded companies with less than $500 million in market capitalization can network with the investment community. The Conference will feature presentations by CEOs and CFOs from various industry sectors, expert panels, and the opportunity to meet with management of presenting companies on a one-on-one basis.
LTEA: 4.59 (+0.35)
SeeThruEquity Initiates Coverage on Endonovo Therapeutics, Inc. (OTCQB: ENDV) with a Price Target Price of $1.15
ACCESSWIRE - Wed May 25, 8:00AM CDT
NEW YORK, NY / ACCESSWIRE / May 25, 2016 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has initiated coverage on Endonovo Therapeutics, Inc. (OTCQB: ENDV) with a price target of $1.15.
6 Biotech Stocks That Will Heat Up Heading Into The Summer
ACCESSWIRE - Fri May 20, 8:00AM CDT
LAS VEGAS, NV / ACCESSWIRE / May 20, 2016 / As summer approaches, the weather continues getting hotter across the country and these 6 biotechnology companies could help investors surf a wave of profits from June to August.
GALE: 0.41 (-0.01)
Endonovo Therapeutics to Present at the 2016 Marcum Microcap Conference in New York
Marketwired - Thu May 05, 1:47PM CDT
LOS ANGELES, CA--(Marketwired - May 5, 2016) - Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"
, an innovative biotechnology company developing a bioelectronic approach to regenerative medicine, announced today that Endonovo Chairman & CEO, Alan Collier, will present a company overview at the 2016 Marcum Microcap Conference on June 2, 2016. The event will be held at the Grand Hyatt New York on Park Avenue at Grand Central.
Biotech Quietly Preparing Technical Breakouts
ACCESSWIRE - Mon Apr 18, 8:17AM CDT
LA VEGAS, NV / ACCESSWIRE / April 18, 2016 / Both pharmaceutical and biotech stocks had a rough year but technical indicators suggest that perhaps the bear market on these sectors is over. One company we are very bullish on is Endonovo Therapeutics, Inc. (ENDV).
IBB: 291.09 (-4.12), PTCT: 8.17 (-0.02)
Endonovo Therapeutics to Present at the SeeThruEquity 5th Annual Microcap Investor Conference in New York
Marketwired - Wed Apr 13, 7:34AM CDT
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company", an innovative biotechnology company developing bioelectronic products and therapies for regenerative medicine, announced today that Endonovo Chairman & CEO, Alan Collier, will present a company and bioelectronics overview at the SeeThruEquity 5th Annual Microcap Investor Conference on May 31, 2016. The event will be held at Convene Conference Center at 730 3rd Avenue in New York City.
Six Technologies That Will Change Healthcare
ACCESSWIRE - Thu Apr 07, 8:32AM CDT
LAS VEGAS, NV / ACCESSWIRE / April 7, 2016 / Here are 6 technologies that will change the face of the global healthcare market in the next 5 years.
CARA: 6.29 (-0.27)
Endonovo Therapeutics Receives USPTO Notice of Allowance for Patent Covering Production of Biomolecules From Adult Stem Cells
Marketwired - Wed Mar 30, 2:12PM CDT
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company", an innovative biotechnology company developing bioelectronics-based products and therapies for regenerative medicine, announced today it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent application entitled "Biological Molecules Produced by Electromagnetically Stimulating Living Mammalian Cells."
Why Investors Are So Bullish on This Small Biotech
ACCESSWIRE - Wed Mar 30, 9:30AM CDT
LAS VEGAS, NV / ACCESSWIRE / March 30, 2016 / One major shift we are looking for in healthcare in the coming months is an increased emphasis on bio-electronic medicine, as opposed to pure drug plays. The reason is that the devices currently under development hold the potential to be more effective, with fewer side effects than traditional drug treatments.
ESPR: 10.79 (-0.20), CMRX: 4.51 (-0.15), GERN: 2.74 (-0.13), CYTX: 2.21 (+0.09), CLDX: 4.42 (-0.04), SGMO: 4.50 (-0.12), PTCT: 8.17 (-0.02), ATHX: 1.98 (-0.04), MNKD: 1.00 (unch)
Booming Orphan Drug Market Provides Investors with Massive Return Prospects
ACCESSWIRE - Wed Mar 30, 6:01AM CDT
WINDSOR, ON / ACCESSWIRE / March 30, 2016 / The Wealthy Biotech Trader (or "WBT", an investment newsletter focused on showing everyday investors new opportunities in rapidly growing, little-known biotech, pharmaceutical and medical device stocks releasing impressive news and making market moves, would like to highlight the massive potential in a number of biotechs pursuing orphan drugs.
CPXX: 30.24 (unch), DMPI: 6.45 (-0.10), DNAI: 1.93 (-0.07)
Why Healthcare Investors Should Forget about Drug Companies and Focus on Medical Device Companies
ACCESSWIRE - Mon Mar 21, 12:25PM CDT
WINDSOR, ON / ACCESSWIRE / March 21, 2016 / The Wealthy Biotech Trader (or "WBT", is an investment newsletter focused on presenting everyday investors new opportunities in rapidly growing, little-known, biotech, pharma and medical device stocks, which are making news and subsequent market moves. WBT would like to shed some light on the bubble among the big pharma companies and draw attention to smaller, yet highly innovative companies making their presence felt in the medical device sector. We will focus on our highlighted company, Endonovo Therapeutics, Inc. (OTCQB: ENDV), which we will compare to and contrast to a few others in the space.
CSII: 22.33 (+0.12), TROV: 5.59 (-0.12)
Biotech Trade Alert
ACCESSWIRE - Tue Mar 15, 11:50AM CDT
LAS VEGAS, NV / ACCESSWIRE / March 15, 2016 / We are issuing an immediate trade alert on Endonovo Therapeutics (OTCQB: ENDV) and a few other biotech companies.
ESPR: 10.79 (-0.20), VCEL: 2.13 (-0.03), SGMO: 4.50 (-0.12), ZYNE: 10.04 (-0.79)
Biotech's in the News
ACCESSWIRE - Wed Aug 10, 9:19AM CDT
LAS VEGAS, NV / ACCESSWIRE / August 10, 2016 / The name of the game in evaluating development stage biotechnology is patents. How many do they have, how useful are they, and how likely is it they will produce treatments or products for the market? Depending on the combination of answers said company could become an enticing acquisition candidate for some of the bigger fish in the biotech world. Which tends to pay companies and their investors premiums to circumvent their lack of R&D.
BCRX: 4.37 (-0.35), BLCM: 19.72 (+0.54)
Endonovo Therapeutics Files Patent for Treating Chemical and Radiation Injuries Using Next-Generation Biologics
Marketwire Canada - Wed Aug 10, 7:05AM CDT
Next-Generation Biologics Include Cell Therapies and Human Biomolecules Produced by Electromagnetic Stimulation of Adult Stem Cells
Endonovo Therapeutics Announces Issuance of U.S. Patent on Production of Human Biomolecules
Marketwire Canada - Tue Aug 09, 6:00AM CDT
Key Patent Covers Production of Human Proteins Used as Biologics, including EPO, G-CSF, GM-CSF, and IL-2
These Biotech's are Due for a Run
ACCESSWIRE - Thu Aug 04, 12:09PM CDT
It's an Interesting Time in the Biotech Market, and with Labor Day on the Horizon, here's a few Biotechs that could Bring You Closer to Financial Independence
ACRX: 3.57 (-0.10), GSK: 44.32 (-0.08)
OTCQX and OTCQB Companies to Present at 2016 Marcum MicroCap Conference
PR Newswire - Tue May 31, 5:49PM CDT
OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the lineup of OTCQX® Best and OTCQB® Venture Market companies presenting at the Marcum MicroCap Conference, taking place June 1-2nd at the Grand Hyatt New York. The Marcum MicroCap Conference, is dedicated to providing a forum where publicly traded companies with less than $500 million in market capitalization can network with the investment community. The Conference will feature presentations by CEOs and CFOs from various industry sectors, expert panels, and the opportunity to meet with management of presenting companies on a one-on-one basis.
LTEA: 4.59 (+0.35)
SeeThruEquity Initiates Coverage on Endonovo Therapeutics, Inc. (OTCQB: ENDV) with a Price Target Price of $1.15
ACCESSWIRE - Wed May 25, 8:00AM CDT
NEW YORK, NY / ACCESSWIRE / May 25, 2016 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has initiated coverage on Endonovo Therapeutics, Inc. (OTCQB: ENDV) with a price target of $1.15.
6 Biotech Stocks That Will Heat Up Heading Into The Summer
ACCESSWIRE - Fri May 20, 8:00AM CDT
LAS VEGAS, NV / ACCESSWIRE / May 20, 2016 / As summer approaches, the weather continues getting hotter across the country and these 6 biotechnology companies could help investors surf a wave of profits from June to August.
GALE: 0.41 (-0.01)
Endonovo Therapeutics to Present at the 2016 Marcum Microcap Conference in New York
Marketwired - Thu May 05, 1:47PM CDT
LOS ANGELES, CA--(Marketwired - May 5, 2016) - Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"
, an innovative biotechnology company developing a bioelectronic approach to regenerative medicine, announced today that Endonovo Chairman & CEO, Alan Collier, will present a company overview at the 2016 Marcum Microcap Conference on June 2, 2016. The event will be held at the Grand Hyatt New York on Park Avenue at Grand Central. Biotech Quietly Preparing Technical Breakouts
ACCESSWIRE - Mon Apr 18, 8:17AM CDT
LA VEGAS, NV / ACCESSWIRE / April 18, 2016 / Both pharmaceutical and biotech stocks had a rough year but technical indicators suggest that perhaps the bear market on these sectors is over. One company we are very bullish on is Endonovo Therapeutics, Inc. (ENDV).
IBB: 291.09 (-4.12), PTCT: 8.17 (-0.02)
Endonovo Therapeutics to Present at the SeeThruEquity 5th Annual Microcap Investor Conference in New York
Marketwired - Wed Apr 13, 7:34AM CDT
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"
, an innovative biotechnology company developing bioelectronic products and therapies for regenerative medicine, announced today that Endonovo Chairman & CEO, Alan Collier, will present a company and bioelectronics overview at the SeeThruEquity 5th Annual Microcap Investor Conference on May 31, 2016. The event will be held at Convene Conference Center at 730 3rd Avenue in New York City. Six Technologies That Will Change Healthcare
ACCESSWIRE - Thu Apr 07, 8:32AM CDT
LAS VEGAS, NV / ACCESSWIRE / April 7, 2016 / Here are 6 technologies that will change the face of the global healthcare market in the next 5 years.
CARA: 6.29 (-0.27)
Endonovo Therapeutics Receives USPTO Notice of Allowance for Patent Covering Production of Biomolecules From Adult Stem Cells
Marketwired - Wed Mar 30, 2:12PM CDT
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"
, an innovative biotechnology company developing bioelectronics-based products and therapies for regenerative medicine, announced today it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent application entitled "Biological Molecules Produced by Electromagnetically Stimulating Living Mammalian Cells." Why Investors Are So Bullish on This Small Biotech
ACCESSWIRE - Wed Mar 30, 9:30AM CDT
LAS VEGAS, NV / ACCESSWIRE / March 30, 2016 / One major shift we are looking for in healthcare in the coming months is an increased emphasis on bio-electronic medicine, as opposed to pure drug plays. The reason is that the devices currently under development hold the potential to be more effective, with fewer side effects than traditional drug treatments.
ESPR: 10.79 (-0.20), CMRX: 4.51 (-0.15), GERN: 2.74 (-0.13), CYTX: 2.21 (+0.09), CLDX: 4.42 (-0.04), SGMO: 4.50 (-0.12), PTCT: 8.17 (-0.02), ATHX: 1.98 (-0.04), MNKD: 1.00 (unch)
Booming Orphan Drug Market Provides Investors with Massive Return Prospects
ACCESSWIRE - Wed Mar 30, 6:01AM CDT
WINDSOR, ON / ACCESSWIRE / March 30, 2016 / The Wealthy Biotech Trader (or "WBT"
, an investment newsletter focused on showing everyday investors new opportunities in rapidly growing, little-known biotech, pharmaceutical and medical device stocks releasing impressive news and making market moves, would like to highlight the massive potential in a number of biotechs pursuing orphan drugs. CPXX: 30.24 (unch), DMPI: 6.45 (-0.10), DNAI: 1.93 (-0.07)
Why Healthcare Investors Should Forget about Drug Companies and Focus on Medical Device Companies
ACCESSWIRE - Mon Mar 21, 12:25PM CDT
WINDSOR, ON / ACCESSWIRE / March 21, 2016 / The Wealthy Biotech Trader (or "WBT"
, is an investment newsletter focused on presenting everyday investors new opportunities in rapidly growing, little-known, biotech, pharma and medical device stocks, which are making news and subsequent market moves. WBT would like to shed some light on the bubble among the big pharma companies and draw attention to smaller, yet highly innovative companies making their presence felt in the medical device sector. We will focus on our highlighted company, Endonovo Therapeutics, Inc. (OTCQB: ENDV), which we will compare to and contrast to a few others in the space. CSII: 22.33 (+0.12), TROV: 5.59 (-0.12)
Biotech Trade Alert
ACCESSWIRE - Tue Mar 15, 11:50AM CDT
LAS VEGAS, NV / ACCESSWIRE / March 15, 2016 / We are issuing an immediate trade alert on Endonovo Therapeutics (OTCQB: ENDV) and a few other biotech companies.
ESPR: 10.79 (-0.20), VCEL: 2.13 (-0.03), SGMO: 4.50 (-0.12), ZYNE: 10.04 (-0.79)
